Form 4: Emergent BioSolutions SVP's Equity Award Vesting

Emergent BioSolutions SVP William Hartzel's performance stock units vested at 25% of target, resulting in a net acquisition of 1,922 shares after tax withholding.

Summary

• SVP William Hartzel's performance stock units (PSUs) for the 2023-2025 period vested on February 6, 2026.
• The Compensation Committee certified the achievement at a 25% payout factor of the target.
• This resulted in an actual award of 1,922 shares of common stock, which was significantly less than the 7,693 shares previously reported on March 2, 2023, and June 9, 2023.
• An additional 630 shares were withheld to cover taxes associated with the vesting and settlement of restricted stock units.
• Following these transactions, Mr. Hartzel beneficially owns 96,681 shares of common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative indicator for the company's recent financial performance, given the significantly underachieved performance stock unit payout for a senior executive.

Negatives

• Performance stock units for 2023-2025 vested at only 25% of the target payout factor.
• The actual award of 1,922 shares was substantially lower than the 7,693 shares previously anticipated.

Risks

• The low payout factor (25% of target) for performance stock units indicates that Emergent BioSolutions Inc. did not meet its cumulative revenue and adjusted EBITDA targets for the 2023-2025 period.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive compensation tied to performance metrics like revenue and EBITDA is a standard practice in the biotechnology and pharmaceutical industries. The low payout factor for Emergent BioSolutions' SVP suggests the company may have faced challenges in meeting its financial targets during the 2023-2025 period, potentially reflecting broader industry headwinds or specific company operational issues.

Comparison to Industry Standards

• Performance-based equity awards are common across the biotech and pharma sectors, with companies like Pfizer, Johnson & Johnson, and Moderna frequently using similar structures to align executive incentives with long-term financial performance.
• A 25% payout factor for PSUs is significantly below typical target achievement rates, which often range from 75% to 125% for companies meeting or exceeding expectations. This suggests underperformance relative to industry peers who successfully hit their financial milestones.
• For example, a company like Gilead Sciences might see PSU payouts closer to 100% or more if their drug development milestones and revenue targets are met, contrasting sharply with Emergent BioSolutions' reported 25%.

Stakeholder Impact

• Shareholders: The low PSU payout suggests the company did not meet its financial performance targets, which could negatively impact shareholder confidence and stock valuation.
• Employees: Executive compensation outcomes can influence overall employee morale and perception of company performance.

Key Dates

Recommendation

The significantly underachieved performance stock unit payout (25% of target) for a Senior Vice President indicates that Emergent BioSolutions Inc. failed to meet its critical financial targets (cumulative revenues and adjusted EBITDA) for the 2023-2025 period. This fundamental underperformance suggests underlying operational or market challenges that could negatively impact future earnings and stock value, warranting a sell recommendation for investors.

Keywords

Emergent BioSolutions, EBS, Form 4, insider transaction, performance stock units, PSU, equity compensation, executive compensation, stock vesting